The Liposome Service ecosystem spans upstream raw‑material sourcing, midstream formulation and manufacturing capabilities, and downstream delivery to pharmaceutical and biotech end users. Upstream, specialized chemical producers supply phospholipids, cholesterol, and stabilizers that define membrane composition. Midstream, technology providers and contract manufacturing organizations (CMOs) translate these inputs into defined liposomal products using microfluidic, extrusion, or freeze‑drying platforms, while embedding analytical controls for size distribution and payload loading. Downstream, distributors, logistics firms, and regulatory advisors channel finished services to drug developers, who embed liposomes into vaccines, oncology agents, or gene‑therapy vectors. Value is captured through service fees, intellectual‑property licensing, and downstream product royalties, with cost structures linked to batch scale and customization depth.